Reslo Life Science

Reslo is a Dublin-based biotechnology company focused on developing first-in-class small molecule therapies for chronic inflammatory and autoimmune diseases. The company's approach is rooted in the field of immunometabolism, specifically targeting mitochondrial pathways that act as master switches for immune cell activation. By modulating enzymes such as succinate dehydrogenase, Reslo aims to suppress the production of pro-inflammatory cytokines and restore immune homeostasis. The company was co-founded by Professor Luke O'Neill, a leading expert in innate immunity, and is backed by prominent life science investors. Reslo's platform offers a novel way to treat inflammation without the broad immunosuppression associated with current standard-of-care treatments.